Friday, December 03, 2021 1:48:14 PM
Scripts for week ending November 26, 2021 Thanksgiving
Overall drug TRx: -12.3%
Vascepa
TRx 68,451; -13.1% (-10,284) w/w; -4.7% y/y
NRx 28,737; -18.9% (-6,688) w/w; -5.8% y/y
Ref 39,714; -8.3% (-3,597) w/w; -3.9% y/y
Lovaza (Generic & Brand)
TRx 52,950; -16.6% (-10,515) w/w; -1.7% y/y
NRx 24,681; -20.7% (-6,436) w/w; -5.4% y/y
Ref 28,269; -12.6% (-4,080) w/w; +1.7% y/y
Generic Vascepa
TRx 19,470; -10.8% (-2,347) w/w; As % of total V: 22.1%
NRx 10,590; -12.6% (-1,531) w/w; As % of total V: 26.9%
Ref 8,880; -8.4% (-816) w/w; As % of total V: 18.3%
Generic Vascepa by Manufacturer
Hikma - TRx 11,547 (-2,184); Generic share 59.3%; Total V share 13.1%
Reddy - TRx 7,923 (-163); Generic share 40.7%; Total V share 9.0%
Vascepa + Generic Vascepa
TRx 87,922; -12.6% (-12,631)
NRx 39,328; -17.3% (-8,219)
Ref 48,594; -8.3% (-4,413)
Overall drug TRx: -12.3%
Vascepa
TRx 68,451; -13.1% (-10,284) w/w; -4.7% y/y
NRx 28,737; -18.9% (-6,688) w/w; -5.8% y/y
Ref 39,714; -8.3% (-3,597) w/w; -3.9% y/y
Lovaza (Generic & Brand)
TRx 52,950; -16.6% (-10,515) w/w; -1.7% y/y
NRx 24,681; -20.7% (-6,436) w/w; -5.4% y/y
Ref 28,269; -12.6% (-4,080) w/w; +1.7% y/y
Generic Vascepa
TRx 19,470; -10.8% (-2,347) w/w; As % of total V: 22.1%
NRx 10,590; -12.6% (-1,531) w/w; As % of total V: 26.9%
Ref 8,880; -8.4% (-816) w/w; As % of total V: 18.3%
Generic Vascepa by Manufacturer
Hikma - TRx 11,547 (-2,184); Generic share 59.3%; Total V share 13.1%
Reddy - TRx 7,923 (-163); Generic share 40.7%; Total V share 9.0%
Vascepa + Generic Vascepa
TRx 87,922; -12.6% (-12,631)
NRx 39,328; -17.3% (-8,219)
Ref 48,594; -8.3% (-4,413)
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
